Effect of morphine and lacosamide on levels of dopamine and 5-HIAA in brain regions of rats with induced hypoglycemia.
The study aimed to determine the effect of morphine and lacosamide on levels of dopamine and 5-HIAA in a hypoglycemic model. Female Wistar rats (n = 30), mean weight of 180 g were treated as follow: Group 1 (control) received 0.9% NaCl, Group II; morphine (10 mg kg(-1)), Group III; lacosamide (10 mg kg(-1)), Group IV; insulin (10 U.I. per rat), Group V; morphine (10 mg kg(-1))+insulin, Group VI; lacosamide (10 mg kg(-1))+ insulin. All administrations were made intraperitoneally every 24 h, for 5 days. Animals were sacrificed after the last dose to measure the levels of glucose in blood; dopamine and 5-HIAA in cortex, hemispheres and cerebellum/medulla oblongata regions. Levels of glucose decreased significantly in animals treated with morphine, lacosamide and all groups that received insulin alone or combined with respect to control group. Levels of Dopamine diminished significantly in cortex and increased significantly in hemispheres of animals that received morphine. In cortex, 5-HIAA increase significantly in the groups treated with morphine, morphine+insulin and lacosamide+insulin, however a significant decrease of the same substance was witnessed in cerebellum and medulla oblongata of animals that received morphine or lacosamide plus insulin. GSH increased significantly in cortex and cerebellum/medulla oblongata of animals treated with morphine and lacosamide alone or combined with insulin. Lipid peroxidation decreased significantly in cortex and cerebellum/medulla oblongata of groups that received lacosamide alone or combined with insulin. These results indicate that hypoglycemia induced changes in cellular regulation while morphine and lacosamide are accompanied by biochemical responses.
D Calderon
DC
Guzman
E Hernandez
EH
Garcia
G Barragan
GB
Mejia
H Juarez
HJ
Olguin
J A Saldivar
JA
Gonzalez
N A
NA
Labra Ruiz
D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002531:Cerebellum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism*; D007003:Hypoglycemia / Q000378:metabolism*; D007328:Insulin / Q000378:metabolism; D000078334:Lacosamide; D015227:Lipid Peroxidation / Q000187:drug effects; D008526:Medulla Oblongata / Q000187:drug effects* / Q000378:metabolism; D009020:Morphine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D000081:Acetamides; D001786:Blood Glucose; D007328:Insulin; D006897:Hydroxyindoleacetic Acid; D000078334:Lacosamide; D009020:Morphine; D004298:Dopamine